Replies to post #5924 on NorthWest Biotherapeutics Inc (NWBO)

[flipper44]

To my knowledge there is another interim look at 88 events, and a final look at 112 events. These looks may be moot if the DMC finds statistical efficacy for the current (66 event) review.

At the 88th event, they can review the statistical powering to see if they need to increase the size of the group -- IMHO that modification possibility is relatively unlikely. However, if it occurred, I'm not certain which group they would adjust -- the pseudo-progression or the primary-endpoint group.